Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer
- Authors:
- Published online on: February 14, 2017 https://doi.org/10.3892/ol.2017.5739
- Pages: 2483-2489
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Tumor protein 53 (TP53), a tumor suppressor gene, is a vital cellular cancer suppressor in multicellular organisms. Murine double minute-2 (MDM2) is an oncoprotein that inhibits TP53 activity. A number of studies have examined the association of TP53 and MDM2 polymorphisms with the risk of common forms of cancer, but the findings remain inconclusive. The present study aimed to evaluate the impact of the 40‑bp insertion/deletion (I/D) polymorphism (rs3730485) in the MDM2 promoter region and the 16‑bp I/D polymorphism (rs17878362) in TP53 on the susceptibility of prostate cancer (PCa) in a sample of the Iranian population. This case‑control study included 103 patients with pathologically confirmed PCa and 142 patients with benign prostatic hyperplasia. The MDM2 40‑bp I/D and TP53 16‑bp I/D polymorphism was determined using polymerase chain reaction analysis. The results demonstrated that the MDM2 40‑bp I/D polymorphism increased the risk of PCa in a co‑dominant inheritance model [odds ratio (OR)=1.88; 95% confidence interval (CI)=1.11‑3.19; P=0.023, D/D vs. I/I], while this variant marginally increased the risk of PCa in a dominant model (OR=1.69; 95% CI=1.00‑2.83; P=0.051, I/D+D/D vs. I/I). No significant association was observed between the TP53 16-bp I/D polymorphism and PCa. In conclusion, the present study demonstrated that the 40‑bp I/D polymorphism in the MDM2 promoter increased the risk of PCa in an Iranian population. Further investigations with diverse ethnicities and larger sample sizes are required to verify these results.
